Inna Yuryev-Golger, MD
Psychiatry · Brooklyn, NYNPI 1053324780
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 3 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Vanda Pharmaceuticals Inc. accounts for 67.3% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for psychiatry clinicians in NY, where the typical reported total is $125.
Across 3 payments — averaging $15.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vanda Pharmaceuticals Inc.$32
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$16
Across 530 payments — averaging $5716.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$639K
- Sage Therapeutics, LLC$580K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$346K
- Avanir Pharmaceuticals, Inc.$346K
- H. Lundbeck A S$275K
- AbbVie$192K
- plus $651K from 12 others
What the payments were for
- Food & beverage$48100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 2 | $32 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
How this compares
$48 in reported general payments places this provider in the 35th percentile of 3,713 psychiatry providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 224 | $356,499 |
| NamzaricMemantine Hcl/Donepezil Hcl | 119 | $72,749 |
| VraylarCariprazine Hcl | 45 | $59,877 |
| TrintellixVortioxetine Hydrobromide | 40 | $22,236 |
| Memantine Hcl ErMemantine Hcl | 307 | $19,608 |
| ExelonRivastigmine | 25 | $16,846 |
| Memantine Hcl | 1,168 | $15,070 |
| SaphrisAsenapine Maleate | 12 | $12,550 |
| Rivastigmine | 130 | $11,816 |
| VascepaIcosapent Ethyl | 43 | $11,464 |
| RivastigmineRivastigmine Tartrate | 507 | $10,143 |
| FetzimaLevomilnacipran Hcl | 16 | $7,694 |
| Mirtazapine | 818 | $6,899 |
| Lurasidone Hcl | 34 | $6,603 |
| Namenda XrMemantine Hcl | 14 | $5,954 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Brooklyn
- Mark OwensBrooklyn$286K
- Nancy Abdel-WahabBrooklyn$253K
- Stephan CarlsonBrooklyn$184K
- Louis BelzieBrooklyn$161K
- Nikhil PalekarBrooklyn$115K
- Alexander PinkusovichBrooklyn$95K
- Leslie CitromePomona$5.7M
- Sanjay GuptaCheektowaga$1.9M
- Richard PriceMonsey$1.7M
- Adam AshtonAmherst$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.